Radiation plus immunotherapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of targeted radiation (photon radiotherapy) with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer that can't be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have liver cancer (HCC) that cannot be removed by surgery or transplant, with tumors smaller than 20 cm total and no single tumor larger than 15 cm.
- Your liver function must be fairly good (Child-Pugh score of 5 or 6) and your cancer stage must be intermediate (B) or advanced (C).
- You should have no untreated active hepatitis B or C, no prior radiation to the liver area, and no distant spread that can't be covered by the study's radiation.
- You must be 18 or older, have a good performance status (able to do daily activities), and have adequate blood counts, kidney, and liver lab results.
- You cannot have certain health issues like unstable heart disease, recent bleeding, active autoimmune disease, or a history of organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining proton beam radiation with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer (HCC) that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of liver-directed radiation therapy, an immunotherapy drug (which helps your immune system fight cancer), and a drug that blocks blood vessel growth to the tumor. It is for people with advanced liver cancer that cannot be treated with surgery.
This study tests a new combination for liver cancer that has not responded to one earlier treatment. It uses a focused type of radiation (SBRT) plus an immunotherapy drug called QL1706 (a medicine that helps your immune system attack cancer). The goal is to see if this combination can control the cancer better.
This trial tests a combination of radiation therapy, an immunotherapy drug (tislelizumab), and a targeted therapy drug (anlotinib) for people with liver cancer that has spread into the main blood vessel of the liver (portal vein). The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests adding two immunotherapy and anti-angiogenesis drugs (atezolizumab and bevacizumab) to standard photon radiation for people with liver cancer that cannot be surgically removed. It aims to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) plus targeted proton radiation for liver cancer that cannot be removed by surgery. The goal is to see if this approach can shrink tumors and improve outcomes for people with intermediate or advanced stage liver cancer.
Hear when a new Durvalumab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.